Discovery of Ganglioside GM2 Activator as a Novel Proteomic Biomarker Associated with Response to Treatment in First-line Melanoma Subjects Treated with PD-1 Immunotherapy
K. Beeler1, J. Vowinckel1, M. Soste1, D. Mallardo2, M. Capone2, M. Gabriele2, A. Sorrentino2, V. Vanella2, K. Sklodowski2, D. Heinzmann2, P. Ascierto2
1) Biognosys AG, Schlieren (Zurich), Switzerland 2) Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy
Integrating Deep Proteomic Profiling with Survival Analysis to Identify Novel Biomarkers of Response to PD-1 Blockade in NSCLC Patients
V. Dozio1, S. Lopez-Lastra3, A. Lanzós1, K. Sklodowski1, K. Beeler1, E. Romano2, 3
1) Biognosys AG, Schlieren (Zurich), Switzerland 2) Medical Oncology Department, Institut Curie, Paris, France 3) Center for Cancer Immunotherapy, Institut Curie, Paris, France
The ESMO Virtual Exhibition takes place from Tuesday 10 November to Sunday 15 November 2020. Check out our virtual booth and chat live with our team via the virtual platform.
More information about our offerings for Oncology Research is available
More information about our offerings for Clinical Studies is available
More information about our offerings for Pre-clinical Evaluation is available
More information about our offerings for Discovery Biology is available
Access our knowledge base with relevant resources and guiding information.